Veranova Appoints Matteo Villain as VP of Peptides and Oligonucleotides
Veranova appoints Matteo Villain as Vice President of Peptides and Oligonucleotides. Villain will bring extensive expertise in peptide and oligonucleotide development and manufacturing to Veranova as the company continues to strengthen its position as a key player in the Peptide and Oligonucleotide (TIDES) space.
“Villain, and his holistic experience in the development and manufacturing of peptide APIs, will be a tremendous asset to Veranova,” says Rohtash Kumar, Senior Vice President of Development Operations and Chief Technology Officer. Kumar added, “we have great momentum right now following our ongoing investment in the bioconjugation sector as well as the recent groundbreaking of our HPAPI and ADC expansion in Devens. This additional investment in leading talent will support our growing presence in the TIDES space, in further support of our strategic initiatives and vision.”
Villain is a seasoned CMC leader with 40 years of experience in peptide drug substance development, process scale-up, cGMP manufacturing, and regulatory compliance. He held senior roles at Bachem Americas, leading the development of over 60 peptide APIs, and later founded MV API Consulting and served as Vice President and Global Peptides Technical Lead at Piramal Pharma Solutions. Villain holds a doctorate in Medicinal Chemistry and Pharmaceutical Science from the University of Milan, completed postdoctoral fellowships in the US and Switzerland, and has contributed to industry workshops and presentations.
